Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 2
Submit an article Journal homepage
70
Views
34
CrossRef citations to date
0
Altmetric
Review

Recent developments in the discovery of hepatitis C virus serine protease inhibitors – towards a new class of antiviral agents?

Frank Narjes IRBM-Merck Research Laboratories Rome,Via Pontina Km 30,600,00040 Pomezia, Italy. [email protected]
,
Uwe Koch IRBM-Merck Research Laboratories Rome,Via Pontina Km 30,600,00040 Pomezia, Italy. [email protected]
&
Christian Steinkühler IRBM-Merck Research Laboratories Rome,Via Pontina Km 30,600,00040 Pomezia, Italy. [email protected]
Pages 153-163 | Published online: 02 Mar 2005

Bibliography

  • CHOO QL, KUO G, WEINER AJ etal.: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 24:359–362.
  • ••Original report describing the firstmolecular cloning of HCV.
  • CORNBERG M, WEDEMEYER H, MANNS MP: Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Carr. Gastroenteral. Rep. (2002) 4:23–30.
  • MANNS MP, MCHUTCHISON JG, GORDON SC et Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358:958–965.
  • ••References 2 and 3 describe the mostefficacious treatment combination presently available.
  • BAZAN JF, FLETTERICK RJ: Detectionof a trypsin-like serine protease motif in flaviviruses and pestiviruses. Virology (1989) 171:637–639.
  • MILLER RH, PURCELL RH: Hepatitis Cvirus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc. Natl. Acad. Sci. USA (1990) 87:2057–2061.
  • LOHMANN V, KOCH JO, BARTENSCHLAGER R: Processing pathways of the hepatitis C virus j Hepatal. (1996) 24:11–19.
  • BARTENSCHLAGER R, AHLBORN-LAAKE L, MOUS J et al.: Kinetic and structural analyses of hepatitis C virus polyprotein processing. j Viral. (1994) 68:5045–5055.
  • FAILLA C, TOMEI L, DE FRANCESCOR: Both N53 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. j Viral. (1994) 68:3753–3760.
  • GRAKOUI A, MCCOURT DW, WYCHOWSKI C et al.: A second hepatitis C virus-encoded proteinase. Proc. Nati Acad. Sci. USA (1993) 90:10583–10587.
  • HIJIKATA M, MIZUSHIMA H, AKAGI T: Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. j Viral. (1993) 67:4665–4675.
  • KOLYKHALOV AA, MIHALIK K, FEINSTONE SM et al.: Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Viral. (2000) 74:2046–2051.
  • •First demonstration that HCV proteases are essential for infectivity.
  • PALLAORO M, LAHM A, BIASIOL G et al.: Characterization of the hepatitis C virus N52/3 processing reaction using a purified precursor protein. I Viral. (2001) 75:9939–9946.
  • WHITNEY M, STACK JH, DARKE PL et al.: A collaborative screening program for the discovery of inhibitors of HCV N52/3 is-cleaving protease activity. J. Biomol. Screen. (2002) 7:149–154.
  • LOHMANN V, KORNER F, KOCH JO et al: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 285:110–113.
  • ••First cell culture system of HCVreplication.
  • BARTENSCHLAGER R: Hepatitis C virus replicons: potential role for drug development. Nature Rev. Drug Discov. (2002) 1:911–916.
  • KOLYKHALOV AA, AGAPOV EV, BLIGHT KJ etal.: Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 277:570–574.
  • ••First demonstration of infection by amolecular clone of the HCV genome.
  • MERCER DE SCHILLER DE, ELLIOTT JF et al: Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. (2001) 7:927–933.
  • ILAN E, ARAZI J, NUSSBAUM O etal.: The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. j Infect Dis. (2002) 185:153–161.
  • KIM JL, MORGENSTERN KA, LIN C et al: Crystal structure of the hepatitis virus NS3 proteinase domain complexed with a syntehtic NS4A cofactor peptide. Cell (1996) 87:343–355.
  • LOVE RA, PARGE HE, WICKERSHAM JA etal.: The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell (1996) 87:331–342.
  • YAN Y, LI Y, MUNSHI S et al: Complex ofNS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 A resolution structure in a hexagonal crystal form. Protein Li. (1998) 7:837–847.
  • BARBATO G, CICERO DO, NARDI C et al: The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J. Mal Biol. (1999) 289:371–384.
  • YAO N, REICHERT P, TAREMI SS et al: Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure Fold Des. (1999) 15:1353–1563.
  • ••References 19–23, describing X-ray and NMR structures, give insight into the mechanisms of activation of the NS3 protease by its cofactor and into the mechanisms and consequences of product inhibition.
  • PIZZI E, TRAMONTANO A, TOMEI L etal.: Molecular model of the specificity pocket of the hepatitis C virus proteinase: implications for substrate recognition. Proc. Natl. Acad. Sci. USA (1994) 91:888–892.
  • •A homology model of the Si pocket of the NS3 protease was used to predict its P1 specificity.
  • FAILLA C, PIZZI E, DE FRANCESCO R etal.: Redesigning the substrate specificity of the hepatitis C virus protease. Folding Design (1996) 1:35–42.
  • KOCH JO, BARTENSCHLAGER R: Determinants of substrate specificity in the NS3 serine proteinase of the hepatitis C virus. Virology (1997) 237:78–88.
  • BARTENSCHLAGER R, AHLBORN-LAAKE L, YASARGIL K et al: Substrate determinants for cleavage in cis and in trans by the hepatitis C virus N53 proteinase. Viral (1995) 69:198–205.
  • STEINKUHLER C, BIASIOL G, BRUNETTI M et al: Product inhibition of the hepatitis C virus N53 protease. Biochemistry (1998) 37:8899–8905.
  • LLINAS-BRUNET M, BAILEY M, FAZAL G et al.: Peptide based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett.(1998) 8:1713–1718.
  • INGALLINELLA P, ALTAMURA S, BIANCHI E et al.: Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimising the cleavage products. Biochemistry (1998) 37:8906–8914.
  • ••References 28–30 describe thephenomenon of product inhibition of the N53 protease and how this feature can be used to develop potent peptide inhibitors.
  • URBANI A, BIANCHI E, NARJES F etal.: Substrate specificity of the hepatitis C virus serine protease N53. J. Biol. Chem. (1997) 272:9204–9209.
  • ZHANG R, DURKIN J, WINDSOR WT etal.: Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. j Viral (1997) 71:6208–6213.
  • PACINI L, VITELLI A, FILOCAMO G etal.: In vivo selection of protease cleavage sites by using chimeric sindbis virus libraries. J. Viral (2000) 74:10563–10570.
  • KIM SY, PARK KW, LEE YJ et al: In vivo determination of substrate specificity of hepatitis C virus N53 protease: genetic assay for site-specific proteolysis. Anal. Biochem. (2000) 15:42–48.
  • KOCH U, BIASIOL G, BRUNETTI M et al.: Role of charged residues in the catalytic mechanism of hepatitis C virus N53 protease: electrostatic precollision guidance and transition state stabilization. Biochemistry (2001) 40:631–640.
  • PERNI RB: NS3.4A protease as a target for interfering with hepatitis C virus replication. Drug News Perspect. (2000) 13:69–77.
  • DYMOCK BW, JONES PS, WILSON FX:Novel approaches to the treatment of hepatitis C virus infection. Antiviral Chem. Chemother. (2000) 11:79–96.
  • STEINKOHLER C, KOCH U, NARJES F et al.: Hepatitis C virus serine protease inhibitors: current progress and future challenges. Cum: Med. Chem. (2001) 8:919–932.
  • BEAULIEU PL, LLINAS-BRUNET M: Therapies for hepatitis C infection: targeting the non-structural proteins of HCV. Curr. Med. Chem.: Anti-Infective Agents (2002) 1:163–176.
  • BIANCHI E, PESSI A: Inhibiting viral proteases: Challenges and opportunities. Biopolymers (2002) 66:101–114.
  • TAN SL, PAUSE A, SHI Y: Hepatitis C virus therapeutics: Current status and emerging strategies. Nat. Rev Drug Discov. (2002) 1:867–881.
  • WEST ML, FAIRLIE DP: Targeting HIV protease: a test of drug design methodologies. Trends Pharmacol Sci. (1995) 16:67–75.
  • JOHANSSON A, HUBATSCH I, AKERBLOM E et al.: Inhibition of hepatitis C virus N53 protease activity by product-based peptides is dependent on helicase domain. Bioorg. Med. Chem. Lett. (2001) 11:203–206.
  • JOHANSSON A, POLIAKOV A, AKERBLOM E et al.: Tetrapeptides as potent protease inhibitors of hepatitis C virus full-Length N53 (protease-helicasei NTPase). Bioorg. Med. Chem. (2002) 10:3915–3922.
  • POUPART MA, CAMERON DR, CHABOT C etal.: Solid phase synthesis ofpeptidomimetic inhibitors for the hepatitis C virus protease. j Org. Chem. (2001) 66:4743–4751.
  • LLINAS-BRUNET M, BAILEY M, BORDELEAU J et al.: Discovery of novel tri-peptide inhibitors of the Hepatitis C virus serine protease. Abstr. Pap. Am. Chem. Soc. (2000) 220:MEDI–018.
  • •First report on tripeptide inhibitors of the NS3 protease with cell-based activity.
  • LLINAS-BRUNET M: NS3 serine protease inhibitors as potential antiviral agents for the treatment of hepatitis C virus infections. 3rd International Antiviral & Vaccine Discovery & Development Summit, Princeton, NJ, USA (2002).
  • LLINAS-BRUNET M: XVIIth International Medicinal Chemistry Symposium, Barcelona, Spain (2002).
  • EDE NJ, EAGLE SN, WICKHAM G et al.: Solid phase synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein. j Pept. Li. (2000) 6:11–18.
  • PRIESTLEY ES, DE LUCCA I, GHAVIMI B et al.: P1 Phenethyl peptide boronic acid inhibitors of HCV N53 protease. Bioorg. Med. Chem. Lett. (2002) 12:3199–3202.
  • NARJES F, KOEHLER KF, KOCH U et al: A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV N53 protease. Bioorg. Med. Chem. Lett. (2002) 12:701–704.
  • NARJES E BRUNETTI M, COLARUSSO S et al: Alpha-ketoacids are potent slow binding inhibitors of the Hepatitis C virus N53 protease. Biochemistry (2000) 39: 1849-1861.
  • •References 51 and 52 describe the rational design of a cysteine mimetic and its successful incorporation into mechanism-based inhibitors.
  • COLARUSSO S, GERLACH B, KOCH U et al.: Evolution, synthesis and SAR of tripeptide lalphal-ketoacid Inhibitors of the hepatitis C virus N53/NS4A serine protease. Bioorg. Med. Chem. Lett. (2002) 12:705–708.
  • NIZI E, KOCH U, PONZI S et al.: Capped dipeptide lalphal-Ketoacid inhibitors of the HCV N53 protease. Bioorg. Med. Chem. Lett. (2002) 12:3325–3328.
  • BEEVERS R, CARR MG, JONES PS et al.:Solution and solid-Phase synthesis of potent inhibitors of hepatitis C Virus N53 proteinase. Bioorg. Med. Chem. Lett. (2002) 12:641–643.
  • BENNETT JM, CAMPBELL AD, CAMPBELL AJ et al: The identification of a-ketoamides as potent inhibitors of Hepatitis C virus N53-4A Proteinase. Bioorg. Med. Chem. Lett. (2001) 11:355–357.
  • COLARUSSO S, GERLACH B, KOCH U et al: Solid phase synthesis of novel non-covalent amide inhibitors of the hepatitis C virus serine protease.Drugs Future (2002) 27(Suppl. A):179.
  • INGALLINELLA P, FATTORI D, ALTAMURA S et al.: Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry (2002) 41:5483–5492.
  • •First report on inhibitors binding exclusively to the prime site of a serine protease.
  • SING WT, LEE CL, YEO SL et al.: Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV N53 protease inhibitor. Bioorg. Med. Chem. Lett. (2001) 11:91–94.
  • SPERANDIO D, GANGLOFF AR, LITVAK J et al.: Highly potent non-peptidic inhibitors of the HCV N53/4A serine protease. Bioorg. Med. Chem. Lett. (2002) 12:3129–3133.

Websites

  • http://www.cdc.gov/ncidod/diseases/ hepatitis/slideset/hep_c/ hcv_epi_for_distrib_000925.pdf HEPATITIS BRANCH: CDC- Centers for Disease Control and Prevention Report (2000).
  • http://consensus.nih.gov/cons/116/ Hepc091202.pdf NIH Consensus Development conference statement.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.